Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125262276 | 12526227 | 6 | F | 201606 | 20160913 | 20160705 | 20160923 | PER | US-PFIZER INC-2016287133 | PFIZER | 67.00 | YR | M | Y | 112.00000 | KG | 20160923 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125262276 | 12526227 | 1 | PS | SUTENT | SUNITINIB MALATE | 1 | 37.5 MG, UNK | Y | 21938 | 37.5 | MG | CAPSULE, HARD | |||||||
| 125262276 | 12526227 | 2 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 25 MG, CYCLIC (DAILY FOR 2 WEEKS ON/1 WEEK OFF) | Y | 21938 | 25 | MG | CAPSULE, HARD | ||||||
| 125262276 | 12526227 | 3 | SS | SUTENT | SUNITINIB MALATE | 1 | Oral | 25 MG, CYCLIC (2 WEEKS ON 1 WEEKS OFF) | Y | 21938 | 25 | MG | CAPSULE, HARD | ||||||
| 125262276 | 12526227 | 4 | C | GEMZAR | GEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | UNK, CYCLIC (WEEKLY FOR 2 WEEKS ON / 1 WEEK OFF) | 0 | ||||||||||
| 125262276 | 12526227 | 5 | C | GEMZAR | GEMCITABINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | UNK, CYCLIC, (TAKEN ONCE A WEEK 2 WEEKS ON, 1 WEEK OFF) | 0 | ||||||||||
| 125262276 | 12526227 | 6 | C | METOPROLOL. | METOPROLOL | 1 | UNK | 0 | |||||||||||
| 125262276 | 12526227 | 7 | C | LISINOPRIL. | LISINOPRIL | 1 | UNK, 2X/DAY | 0 | BID | ||||||||||
| 125262276 | 12526227 | 8 | C | LISINOPRIL. | LISINOPRIL | 1 | UNK, 4X/DAY | 0 | QID | ||||||||||
| 125262276 | 12526227 | 9 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | UNK | 0 | |||||||||||
| 125262276 | 12526227 | 10 | C | VITAMIN D | CHOLECALCIFEROL | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125262276 | 12526227 | 1 | Metastatic renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125262276 | 12526227 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125262276 | 12526227 | Abdominal discomfort | |
| 125262276 | 12526227 | Blood creatinine increased | |
| 125262276 | 12526227 | Blood glucose increased | |
| 125262276 | 12526227 | Blood potassium decreased | |
| 125262276 | 12526227 | Blood pressure increased | |
| 125262276 | 12526227 | Diarrhoea | |
| 125262276 | 12526227 | Fatigue | |
| 125262276 | 12526227 | Nausea | |
| 125262276 | 12526227 | Red blood cell count decreased | |
| 125262276 | 12526227 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125262276 | 12526227 | 2 | 20160602 | 0 | ||
| 125262276 | 12526227 | 3 | 20160708 | 0 | ||
| 125262276 | 12526227 | 5 | 20160601 | 20160727 | 0 | |
| 125262276 | 12526227 | 10 | 20160623 | 0 |